A clinical study of KD045 for the treatment of fibrotic diseases
Latest Information Update: 05 Jul 2022
Price :
$35 *
At a glance
- Drugs KD 045 (Primary)
- Indications Fibrosis
- Focus Adverse reactions
- 09 May 2019 New trial record
- 07 Mar 2019 According to the Kadmon Holdings media release, company expects to initiate this study in 2H 2019.